University of Alberta’s cancer treatment advances to human trial
Category: #health  By Pankaj Singh  Date: 2020-05-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

University of Alberta’s cancer treatment advances to human trial

The treatment would be tested on stage four cancer patients who have not shown response to currently available treatments.

University of Alberta has reportedly taken a pioneering step towards developing a treatment for cancer as it announces commencement of its human trial for new cancer drug dubbed, PCLX-001, in three Canadian cities by late 2020.

According to reliable sources, researchers have discovered that a compound earlier developed in a Scottish university to cure African sleeping sickness could shrink cancerous human tumors when trialed on mice. PCLX-001 was developed by Pacylex, a spinoff company of the University of Alberta, and is set to be tested on stage four cancer patients who are not responding to existing treatments.

Reportedly, Luc Berthiaume, Pacylex’s Co-Founder and a cell biology professor at U of A, begun researching on the compound almost 10 years ago. Berthiaume claims that the lab tests showed PCLX-001 was more efficient than the two prominent drugs for leukemia and lymphoma. Besides, it also showed a strong potential against colon, lung, and breast cancers.

Speaking on the move, Dr. John Mackey, Co-founder of Pacylex and Director of clinical trials at the Cross Cancer Institute, said that the project has come to an exciting point and is on the verge to potentially make a huge difference in the field of medical science.

Additionally, the drug’s safety was evaluated in pre-clinical models and Pacylex is currently applying for phase one human studies at B.C. Cancer Centre in Vancouver, Princess Margaret Cancer Centre in Toronto, and the Cross Cancer Institute in Edmonton.

In other news, preclinical research conducted by NewYork-Presbyterian investigators and Weill Cornell Medicine revealed that palbociclib could accelerate chemotherapy’s effectiveness in pancreatic cancer if both the treatments are registered in right sequences.

Source Credit: https://edmontonjournal.com/news/local-news/cancer-treatment-developed-at-u-of-a-heading-for-human-drug-trials/



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Pfizer’s XALKORI®) Approved by US FDA for ALK-positive ALCL treatment
Pfizer’s XALKORI®) Approved by US FDA for ALK-positive ALCL treatment
By Pankaj Singh

The pharma giant Pfizer Inc. has reportedly declared that the U.S. Food and Drug Administration (US FDA) has approved the sNDA (supplemental New Drug Application) for XALKORI® (crizotinib) for the treatment of chil...

JCB unites with ACI Worldwide to boost merchant acquiring capabilities
JCB unites with ACI Worldwide to boost merchant acquiring capabilities
By Pankaj Singh

JCB International, a credit card company, has reportedly partnered with ACI Worldwide, a payment system company, to increase merchant acquiring capabilities across the globe.

The To...

Wide occurrence of aortic stenosis to boost transcatheter aortic valve replacement demand
Wide occurrence of aortic stenosis to boost transcatheter aortic valve replacement demand
By Pankaj Singh

Research and development in the global transcatheter heart valve replacement industry have been gathering pace in recent years, with the increasing occurrence of valvular heart diseases and the demand for less invasive...